While acquisition of secondary mutations in the BCR::ABL1 kinase domain is the a common mechanism associated with TKI resistance in CML, in JAK2-driven MPNs secondary mutations in JAK2 are rare. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.